drugset / Trial / NCT01183897
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
Timeline
- Start
- 2010-08-12
- Primary completion
- 2018-09-25
- Completion
- 2018-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3F8 | Monoclonal antibody | 20 mg/m2 | — |
| Subject | 3F8 | Monoclonal antibody | 80 mg/m2 | — |
| Background | Isotretinoin | Other / unclassified | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | — |